For the quarter ended June 2024, Charles River Laboratories (CRL) reported revenue of $1.03 billion, down 3.2% over the same period last year. EPS came in at $2.80, compared to $2.69 in the year-ago quarter. The reported revenue compares to the Zacks Consensus Estimate of $1.03 billion, representing a surprise of +0.09%. The company delivered an EPS surprise of +17.15%, with the consensus EPS estimate being $2.39. While investors closely watch year-over-year changes in headline numbers -- revenue and earnin ...